prikaz prve stranice dokumenta Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
  Preuzmi
PDF 4.2 MB
Znanstveni rad - Izvorni znanstveni rad
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
Journal for ImmunoTherapy of Cancer, 8 (2020), 1; e000266. https://doi.org/10.1136/jitc-2019-000266
Reches, Adi; Ophir, Yael; Stein, Natan; Kol, Inbal; Isaacson, Batya; Charpak Amikam, Yoav; Elnekave, Afek; Tsukerman, Pinchas; Kučan Brlić, Paola; Lenac, Tihana; Seliger, Barbara; Jonjić, Stipan; Mandelboim, Ofer

Citirajte ovaj rad

Reches, A., Ophir, Y., Stein, N., Kol, I., Isaacson, B., Charpak Amikam, Y. ... Mandelboim, O. (2020). Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer, 8. (1). doi: 10.1136/jitc-2019-000266

Reches, Adi, et al. "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity." Journal for ImmunoTherapy of Cancer, vol. 8, br. 1, 2020. https://doi.org/10.1136/jitc-2019-000266

Reches, Adi, Yael Ophir, Natan Stein, Inbal Kol, Batya Isaacson, Yoav Charpak Amikam, Afek Elnekave, et al. "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity." Journal for ImmunoTherapy of Cancer 8, br. 1 (2020). https://doi.org/10.1136/jitc-2019-000266

Reches, A., et al. (2020) 'Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity', Journal for ImmunoTherapy of Cancer, 8(1). doi: 10.1136/jitc-2019-000266

Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, i sur.. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. Journal for ImmunoTherapy of Cancer [Internet]. 06.2020. [pristupljeno 25.04.2024.];8(1). doi: 10.1136/jitc-2019-000266

A. Reches, et al., "Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity", Journal for ImmunoTherapy of Cancer, vol. 8, br. 1, Lipanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:706583. [Citirano: 25.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:706583
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
AutorAdi Reches
AutorYael Ophir
AutorNatan Stein
AutorInbal Kol
AutorBatya Isaacson
AutorYoav Charpak Amikam
AutorAfek Elnekave
AutorPinchas Tsukerman
AutorPaola Kučan Brlić
AutorTihana Lenac
AutorBarbara Seliger
AutorStipan Jonjić
AutorOfer Mandelboim
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za histologiju i embriologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Background The use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack of tumor specificity. Methods We stained human natural killer cells using fusion proteins composed of the extracellular portion of various tumor markers fused to the Fc portion of human IgG1, and identified Nectin4 as a novel TIGIT ligand. Next, we generated a novel Nectin4 blocking antibody and demonstrated its efficacy as a checkpoint inhibitor in killing assays and in vivo. Results We identify Nectin4 to be a novel ligand of TIGIT. We showed that, as opposed to all other known TIGIT ligands, which bind also additional receptors, Nectin4 interacts only with TIGIT. We show that the TIGIT-Nectin4 interaction inhibits natural killer cell activity, a critical part of the innate immune response. Finally, we developed blocking Nectin4 antibodies and demonstrated that they enhance tumor killing in vitro and in vivo. Conclusion We discovered that Nectin4 is a novel ligand for TIGIT and demonstrated that specific antibodies against it enhance tumor cell killing in vitro and in vivo. Since Nectin4 is expressed almost exclusively on tumor cells, our Nectin4-blocking antibodies represent a combination of cancer specificity and immune checkpoint activity, which may prove more effective and safe for cancer immunotherapy.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal for ImmunoTherapy of Cancer
Brojčani podacivol. 8, br. 1, e000266
e-ISSN2051-1426
DOIhttps://doi.org/10.1136/jitc-2019-000266
URN:NBNurn:nbn:hr:184:706583
Datum objave publikacije2020-06
ProjektŠifra: KK.011.1.01.0006
Naziv (engleski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: ERDF
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttps://jitc.bmj.com/lookup/doi/10.1136/jitc-2019-000266
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2020-06-25 14:37:09